422
Views
17
CrossRef citations to date
0
Altmetric
Reviews

Par-4 as a potential target for cancer therapy

, PhD &
Pages 77-87 | Published online: 15 Oct 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jeffrey Q. Nguyen & Rosalyn B. Irby. (2017) TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells. Cancer Biology & Therapy 18:1, pages 16-25.
Read now

Articles from other publishers (16)

Min Tang, Leilei Zhai, Juanjuan Chen, Feng Wang, Haimin Chen & Wei Wu. (2023) The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation. Nutrients 15:9, pages 2044.
Crossref
Daniel Bastida-Ruiz, Alexia Childress & Marie Cohen. 2022. Tumor Suppressor Par-4. Tumor Suppressor Par-4 209 238 .
Anees Rahman Cheratta, Faisal Thayyullathil, Siraj Pallichankandy, Karthikeyan Subburayan, Ameer Alakkal & Sehamuddin Galadari. (2021) Prostate apoptosis response-4 and tumor suppression: it’s not just about apoptosis anymore. Cell Death & Disease 12:1.
Crossref
Jeevan Ghosalkar, Vinay Sonawane, Mohsina Khan, Kalpana Joshi & Padma Shastry. 2021. Tumor Suppressor Par-4. Tumor Suppressor Par-4 77 111 .
Cláudia Malheiros Coutinho-Camillo, Ágatha Nagli de Mello Gomes, Fernanda de Paula, Maria Aparecida Nagai & Silvia Vanessa Lourenço. 2021. Tumor Suppressor Par-4. Tumor Suppressor Par-4 269 279 .
Ge & Kao. (2019) Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target. Cancers 11:11, pages 1787.
Crossref
Renata Virgínia Cavalcanti Santos, Wanessa Layssa Batista de Sena, Flaviana Alves dos Santos, Antônio Felix da Silva Filho, Marina Galdino da Rocha Pitta, Maira Galdino da Rocha Pitta, Moacyr Barreto de Melo Rego & Michelly Cristiny Pereira. (2019) Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where Are We Going?. Current Drug Targets 20:6, pages 635-654.
Crossref
Jian Zhang, Aiyou Sun, Yuguo Dong & Dongzhi Wei. (2017) Recombinant Production and Characterization of SAC, the Core Domain of Par-4, by SUMO Fusion System. Applied Biochemistry and Biotechnology 184:4, pages 1155-1167.
Crossref
Reyaz Ur Rasool, Debasis Nayak, Souneek Chakraborty, Archana Katoch, Mir Mohd Faheem, Hina Amin & Anindya Goswami. (2016) A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4. Clinical & Experimental Metastasis 33:8, pages 757-764.
Crossref
Kevin Brasseur, François Fabi, Pascal Adam, Sophie Parent, Laurent Lessard & Eric Asselin. (2016) Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells. Oncotarget 7:24, pages 36971-36987.
Crossref
Seon Min Woo & Taeg Kyu Kwon. (2016) Par-4 Modulates Cell Migration through Inhibition of MMP-2 Activity in Human Renal Carcinoma Caki Cells. Journal of Life Science 26:5, pages 614-619.
Crossref
Sonia Meynier, Marianne Kramer, Pascale Ribaux, Jean-Christophe Tille, Florence Delie, Patrick Petignat & Marie Cohen. (2015) Role of PAR-4 in ovarian cancer. Oncotarget 6:26, pages 22641-22652.
Crossref
Kevin Brasseur, Pascal Auger, Eric Asselin, Sophie Parent, Jean-Charles Côté & Marc Sirois. (2015) Parasporin-2 from a New Bacillus thuringiensis 4R2 Strain Induces Caspases Activation and Apoptosis in Human Cancer Cells. PLOS ONE 10:8, pages e0135106.
Crossref
Z Wang & W Wei. (2014) Fbxo45 joins the ‘Par-4’ty in controlling apoptosis of cancer cells. Cell Death & Differentiation 21:10, pages 1508-1510.
Crossref
Jayashree C. Jagtap, Parveen Dawood, Reecha D. Shah, Goparaju Chandrika, Kumar Natesh, Anjali Shiras, Amba S. Hegde, Deepak Ranade & Padma Shastry. (2014) Expression and Regulation of Prostate Apoptosis Response-4 (Par-4) in Human Glioma Stem Cells in Drug-Induced Apoptosis. PLoS ONE 9:2, pages e88505.
Crossref
Ling-Jung Wang, Peir-Rong Chen, Lee-Ping Hsu, Wen-Lin Hsu, Dai-Wei Liu, Chung-Hsing Chang, Yih-Chih Hsu & Jeng-Woei Lee. (2014) Concomitant Induction of Apoptosis and Autophagy by Prostate Apoptosis Response-4 in Hypopharyngeal Carcinoma Cells. The American Journal of Pathology 184:2, pages 418-430.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.